Publication related to RSI or an RSI staff member
Diagnosis of manganism and manganese neurotoxicity: A workshop report.
With declining exposures to manganese (Mn) in occupational settings, there is a need for more sensitive exposure assessments and clinical diagnostic criteria for manganism and Mn neurotoxicity. To address this issue, a workshop was held on November 12-13, 2020, with international experts on Mn toxicity. The workshop discussions focused on the history of the diagnostic criteria for manganism, including those developed by the Institut de Recherche Robert-Sauve en Sante et en Securite du Travail (IRSST) in Quebec in 2005 and criteria developed by the Chinese government in 2002 and updated in 2006; the utility of biomarkers of exposure; recent developments in magnetic resonance imaging (MRI) for assessing Mn accumulation in the brain and diagnosing manganism; and potential future applications of metabolomics. The suggestions of the participants for updating manganism diagnostic criteria included the consideration of: i) A history of previous occupational and environmental exposure to Mn; ii) relevant clinical symptoms such as dystonia; iii) MRI imaging to document Mn accumulation in the neural tissues, including the basal ganglia; and iv) criteria for the differential diagnosis of manganism and other neurological conditions. Important research gaps include the characterization of Mn exposure and other co-exposures, exploration of the roles of different brain regions with MRI, understanding the complexity of metal ion transporters involved in Mn homeostasis, and a need for information on other neurotransmitter systems and brain regions underlying the pathophysiology of manganism.
Authors
- Mattison, Donald R, Mattison DR, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; Arnold School of Public Health, University of South Carolina, Columbia, SC 29208, USA.
- Momoli, Franco, Momoli F, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
- Alyanak, Cemil, Alyanak C, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.
- Aschner, Michael, Aschner M, Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
- Baker, Marissa, Baker M, Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA 98195, USA.
- Cashman, Neil, Cashman N, Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.; ProMIS Neurosciences, Inc., Toronto, ON M4S 3E2, Canada.
- Dydak, Ulrike, Dydak U, School of Health Sciences, Purdue University, West Lafayette, IN 47907, USA.
- Farhat, Nawal, Farhat N, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
- Guilarte, Tomas R, Guilarte TR, Department of Environmental Health Sciences, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL 33199, USA.
- Karyakina, Nataliya, Karyakina N, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.
- Ramoju, Siva, Ramoju S, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.
- Shilnikova, Natalia, Shilnikova N, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.; R. Samuel McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
- Taba, Pille, Taba P, Department of Neurology and Neurosurgery, Institute of Clinical Medicine, University of Tartu, 50406 Tartu, Estonia.; Neurology Clinic, Tartu University Hospital, 50406 Tartu, Estonia.
- Krewski, Daniel, Krewski D, Risk Sciences International, Ottawa, ON K1P 5J6, Canada.; School of Epidemiology and Public Health, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.; R. Samuel McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON K1G 5Z3, Canada.
YEAR OF PUBLICATION: 2024
SOURCE: Med Int (Lond). 2024 Feb 6;4(2):11. doi: 10.3892/mi.2024.135. eCollection 2024 Mar-Apr.
JOURNAL TITLE ABBREVIATION: Med Int (Lond)
JOURNAL TITLE: Medicine international
ISSN: 2754-1304 (Electronic) 2754-3242 (Print) 2754-1304 (Linking)
VOLUME: 4
ISSUE: 2
PAGES: 11
PLACE OF PUBLICATION: England
ABSTRACT:
With declining exposures to manganese (Mn) in occupational settings, there is a need for more sensitive exposure assessments and clinical diagnostic criteria for manganism and Mn neurotoxicity. To address this issue, a workshop was held on November 12-13, 2020, with international experts on Mn toxicity. The workshop discussions focused on the history of the diagnostic criteria for manganism, including those developed by the Institut de Recherche Robert-Sauve en Sante et en Securite du Travail (IRSST) in Quebec in 2005 and criteria developed by the Chinese government in 2002 and updated in 2006; the utility of biomarkers of exposure; recent developments in magnetic resonance imaging (MRI) for assessing Mn accumulation in the brain and diagnosing manganism; and potential future applications of metabolomics. The suggestions of the participants for updating manganism diagnostic criteria included the consideration of: i) A history of previous occupational and environmental exposure to Mn; ii) relevant clinical symptoms such as dystonia; iii) MRI imaging to document Mn accumulation in the neural tissues, including the basal ganglia; and iv) criteria for the differential diagnosis of manganism and other neurological conditions. Important research gaps include the characterization of Mn exposure and other co-exposures, exploration of the roles of different brain regions with MRI, understanding the complexity of metal ion transporters involved in Mn homeostasis, and a need for information on other neurotransmitter systems and brain regions underlying the pathophysiology of manganism.
With declining exposures to manganese (Mn) in occupational settings, there is a need for more sensitive exposure assessments and clinical diagnostic criteria for manganism and Mn neurotoxicity. To address this issue, a workshop was held on November 12-13, 2020, with international experts on Mn toxicity. The workshop discussions focused on the history of the diagnostic criteria for manganism, including those developed by the Institut de Recherche Robert-Sauve en Sante et en Securite du Travail (IRSST) in Quebec in 2005 and criteria developed by the Chinese government in 2002 and updated in 2006; the utility of biomarkers of exposure; recent developments in magnetic resonance imaging (MRI) for assessing Mn accumulation in the brain and diagnosing manganism; and potential future applications of metabolomics. The suggestions of the participants for updating manganism diagnostic criteria included the consideration of: i) A history of previous occupational and environmental exposure to Mn; ii) relevant clinical symptoms such as dystonia; iii) MRI imaging to document Mn accumulation in the neural tissues, including the basal ganglia; and iv) criteria for the differential diagnosis of manganism and other neurological conditions. Important research gaps include the characterization of Mn exposure and other co-exposures, exploration of the roles of different brain regions with MRI, understanding the complexity of metal ion transporters involved in Mn homeostasis, and a need for information on other neurotransmitter systems and brain regions underlying the pathophysiology of manganism.
COPYRIGHT INFORMATION: Copyright: (c) Mattison et al.
LANGUAGE: eng
DATE OF PUBLICATION: 2024 Mar-Apr
DATE OF ELECTRONIC PUBLICATION: 20240206
DATE REVISED: 20240720
MESH DATE: 2024/02/27 06:45
EDAT: 2024/02/27 06:44
STATUS: PubMed-not-MEDLINE
PUBLICATION STATUS: epublish
LOCATION IDENTIFIER: 10.3892/mi.2024.135 [doi] 11
OWNER: NLM
Related RSI Experts
Chief Risk Scientist
Dr. Daniel Krewski is Chief Risk Scientist and co-founder of Risk Sciences International (RSI), a firm established in 2006 to bring evidence-based, multidisciplinary expertise to the challenge of understanding, managing, and communicating risk. As RSI’s inaugural CEO and long-time scientific...
Chief Medical Officer, Senior Vice-President
Dr. Donald Mattison joined Risk Sciences International (RSI) in 2012 as Senior Vice-President and Chief Medical Officer, bringing with him a distinguished career spanning public health, clinical medicine, toxicology, and academic leadership. His appointment significantly strengthened RSI’s capacity to deliver...
Vice-President Chemical and Product Safety
Dr. Franco Momoli joined Risk Sciences International (RSI) in 2019 and currently serves as Vice-President, Chemical and Product Safety. In this role, he leads a multidisciplinary team of epidemiologists, risk assessors, toxicologists, and biostatisticians in conducting human health risk assessments...
Senior Toxicologist, Health Risk Analyst
Dr. Nataliya Karyakina is a Senior Toxicologist and Health Risk Analyst at Risk Sciences International (RSI), where she has served since 2008. She plays a central role in RSI’s work at the intersection of chemical safety, regulatory science, and human...
Senior Health Risk Analyst
Dr. Natalia (Natasha) Shilnikova is a Senior Health Risk Analyst at Risk Sciences International (RSI), where she has contributed since 2011 to some of the organization’s most analytically demanding and policy-relevant projects. With a background in medicine and a PhD...
Vice-President Communications and Strategic Initiatives
Cemil ‘Jim’ Alyanak joined Risk Sciences International (RSI) in 2018 and serves as Vice-President, Communications and Strategic Initiatives. In this senior leadership role, he leads RSI’s risk communications practice, drives cross-cutting initiatives, advances strategic in-house projects, and expands the company’s...